viewAlibaba Group

Are Alibaba shares a ‘buy’? Goldman Sachs seems to think so

The Wall Street bank repeated its ‘buy’ on the stock in the Chinese e-commerce giant and kept it on the coveted ‘conviction list’ of its top investments

Alibaba Group -

Goldman Sachs has increased its price target for Alibaba (NYSE:BABA) by 14% to US$315 share following last week’s better than expected quarterlies.

It also repeated its ‘buy’ on the stock in the Chinese e-commerce giant and kept it on the coveted ‘conviction list’ of its top investments.

This followed a consensus-beating 34% rise in revenues in the first three months of Alibaba’s financial, which included a full recovery of the group’s domestic business.

“We remain bullish on Alibaba’s market positioning, continuous innovation and strong execution,” said Goldman in a note to

“In additional to China retail, we also expect the company to continue to invest and grow on multiple fronts, including International retail, fintech, local services, cloud computing and online entertainment.”

The hike to the price target was prompted by plugging into its calculations higher earnings and revenue multiples for both the China-based retail business and the AliCloud cloud computing operation.

Also a driver was the increased valuation of Ant Group, owner of Alipay, one of China’s most popular mobile payment apps.

Goldman now reckons Ant is worth US$232bn, compared with its previous estimate of US$209bn.

Quick facts: Alibaba Group


Price: 151.89 USD

Market Cap: $411.76 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Ixico seeing success with a number of contracts awarded covering multiple...

Ixico plc Chief Commercial Officer Lammert Albers joined Steve Darling from Proactive to share news the Clinical Research Organization has awarded the company, on behalf of their biopharmaceutical sponsor,  a 6-figure deal to conduct a Phase II Alzheimer’s disease clinical trial.  Albers...

4 hours, 21 minutes ago

2 min read